Company Overview of OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has c...
800 Chesapeake Drive
Redwood City, CA 94063
Founded in 2004
Key Executives for OncoMed Pharmaceuticals, Inc.
Chairman, Chief Executive Officer and President
Total Annual Compensation: $469.5K
Vice President and General Counsel
Total Annual Compensation: $383.8K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $377.2K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $364.7K
Compensation as of Fiscal Year 2014.
OncoMed Pharmaceuticals, Inc. Key Developments
OncoMed Pharmaceuticals, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-19-2015 02:00 PM
Nov 12 15
OncoMed Pharmaceuticals, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-19-2015 02:00 PM. Venue: The May Fair Hotel, Stratton Street, London, United Kingdom. Speakers: Paul J. Hastings, Chairman, Chief Executive Officer and President.
OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
Nov 7 15
OncoMed Pharmaceuticals Inc. presented new preclinical data for anti-DLL4 combined with anti-VEGF and anti-PD1 during the Society for Immunotherapy of Cancer (SITC) Conference. A series of preclinical experiments compared the impact of anti-DLL4/VEGF bispecific and a triple blockade of DLL4-VEGF-PD1 on anti-tumor immune responses. The combination of anti-DLL4/VEGF and anti-PD1 was found to have more potent anti-tumor and enhanced immuno-oncology activity than either agent alone across a number of measures. The triple blockade of DLL4-VEGF-PD1 significantly inhibited tumor growth with more pronounced tumor regression. The addition of anti-DLL4/VEGF also improved anti-tumor activity of anti-PD1 alone in both PD1 responsive and non-responsive cancers in murine models. DLL4 is a ligand within the Notch pathway and plays important roles in regulating cancer stem cells, tumor angiogenesis and pro-tumor immune responses. OncoMed has two clinical agents targeting DLL4: demcizumab (anti-DLL4, OMP-21M18), currently in Phase 2 trials for the treatment of pancreatic cancer and non-small cell lung cancer (NSCLC), and anti-DLL4/VEGF bispecific, (OMP-305B83) currently in a Phase 1a trial in advanced solid tumors. The combination of anti-DLL4/VEGF bispecific with anti-PD1 demonstrated a distinct mechanistic profile versus prior observations of the synergistic combination of anti-DLL4 and anti-PD1 presented at the American Association for Cancer Research 2015 Annual Meeting, suggesting potential for increased T-cell activation, maintenance and memory T-cell function.
OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 5 15
OncoMed Pharmaceuticals, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. Revenues for the third quarter 2015 totaled $4.7 million, as compared to $19.0 million in the third quarter of 2014. Revenues were higher in the third quarter of 2014 primarily due to milestone revenues from the GlaxoSmithKline and Bayer collaborations achieved during that period. Net loss for the third quarter 2015 was $24.5 million or $0.81 per basic and diluted share, compared to $5.5 million or $0.18 per basic and diluted share for the same three-month period of 2014. The change in net loss for the third quarter of 2015 was primarily due to an increase in operational expenses and lower milestone revenues. Loss from operations was $24,561,000 against $5,500,000 for the same period a year ago. Loss before provision for income taxes was $24,467,000 against $5,451,000 for the same period a year ago.
For the nine months, the company reported collaboration revenue of $19,060,000 against $31,044,000 for the same period a year ago. Loss from operations was $60,737,000 against $34,999,000 for the same period a year ago. Loss before provision for income taxes was $60,594,000 against $34,917,000 for the same period a year ago. Net loss was $60,629,000 compared to $34,954,000 a year ago. Basic and diluted net loss per common share was $2.02 compared to $1.18 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|